Pamlico Biopharma
Oklahoma City
About Pamlico Biopharma
Pamlico BioPharma, Inc. develops fully-human monoclonal antibodies (hmAb) for the rapid diagnosis and treatment of infectious diseases and cancer. Pamlico’s lead program is focused on severe pneumonia caused by Streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. Pamlico was founded on technologies from the Oklahoma Medical Research Foundation (OMRF) and from Emory University, and is anticipated to enter clinical trials in late 2015.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2015)
Industries & Categories
Biopharma, Biotechnology, Clinical Trials, Health Care
Canonical: https://fsome.com/organization/pamlico-biopharma-2311594 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.